Sellas Life Sciences has achieved the 80th event in its Phase 3 REGAL trial of Galinpepimut-S for acute myeloid leukemia. The trial is designed to evaluate the drug's efficacy, with preliminary results anticipated this quarter. Analysts note that prolonged trial durations may enhance the likelihood of failure. The company continues to track the trial's progress closely, with updates projected as the trial progresses. The REGAL trial is a significant step in the development of Galinpepimut-S, which has shown promising results in previous phases. Sellas Life Sciences remains focused on advancing the drug through the regulatory process, with the goal of bringing a potential treatment to patients with acute myeloid leukemia. The company's careful approach to clinical trials and data analysis is strongly regarded in the industry, and investors are watching the trial's outcome with care.